Crossmark

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1186/s13052-023-01543-3

Published Online: 2023-10-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Jing

Hao, Qingfei

Zhang, Jing

Du, Yanna

Chen, Haoming

Cheng, Xiuyong
License Information

Text and Data Mining valid from 2023-10-09

Version of Record valid from 2023-10-09
More Information

Article History

Received: 22 August 2023

Accepted: 26 September 2023

First Online: 9 October 2023

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below